GLP-1 therapies are expanding from metabolic control into broader markets and transformative obesity treatment in the U.S. and India, with low-cost generics changing demand and public perception. Ongoing research explores multispecific GLP-1–based approaches, regenerative implications of GLP-1 signaling, and the optimal timing of GLP-1 therapy around bariatric surgery, suggesting after-MBS initiation may yield the strongest survival and complication benefits.